Inherited Neuropathy Consortium

HNF Joins Inherited Neuropathy Consortium

by | Oct 15, 2018 | 0 comments

HNF would like to announce, with great pleasure, that it has been invited to participate in the Inherited Neuropathy Consortium (INC), one of 22 groups under the Rare Diseases Clinical Research Network (RDCRN), funded primarily by the NIH. The RDCRN was designed to encourage collaboration among scientists from multiple research sites and to include patient advocates to participate and serve as research partners. The network consortium also includes a training program for clinical investigators.

The INC is an integrated group of academic medical centers, patient support organizations, and clinical research resources whose primary purpose is to conduct research. If you are seeking patient care, however, these sites (some of which are HNF Centers of Excellence) also have the knowledge and resources to provide excellent patient care. Since inception in 2009, the INC has conducted research that has enrolled close to 8,000 patients as part of their natural history studies (where patients are followed over time clinically) for a better understanding of CMT.

Additionally, the INC has discovered new biomarkers and has developed special scales to help measure whether treatments are working in the day-to-day life of an individual, leading to deeper scientific understanding of the causes of CMT. It’s important for those patients that have been enrolled in the INC to put as much effort into visiting their admitting site each year to enhance the research program. These studies have forged the path today for industry to develop treatments for us.

To participate in the research, CLICK HERE

The more patients enrolled, the better it is for us!

Allison Moore, HNF CEO will represent HNF as a member of their Coalition of Patient Advocacy Groups (CPAG), which represents the perspective and interests of all patient advocacy organizations associated with the clinical research consortia. Through collaboration, patient advocacy groups and researchers can make faster progress toward new treatment options and cures, which can improve the lives of all persons and families affected by CMT.

“I personally am honored to be part of the consortium that has for sure had an impact on the development of the clinical trials today and for others in the pipeline,” says Allison. “As a representative I will serve our patient community and bring our collective voices to the consortium, as well as support all the consortium members.”

I want to extend a special thank you to Dr. Michael Shy, who is the principal investigator of the INC, for inviting HNF to be part of the consortium.

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news